CLDN18.2: China approved zolbetuximab for first line care - what it means for Indonesian patients
China's regulator, NMPA, approved zolbetuximab in June 2025 as first-line treatment with chemotherapy for advanced CLDN18.2-positive, HER2-negative gastric or gastroesophageal-junction adenocarcinoma. The decision changes what may be worth discussing, but it does not automatically mean the medicine is available in Indonesia or at every hospital in China.
Updated 2026-09-15. For: Families of gastric or GEJ cancer patients with a positive CLDN18.2 result
This is not news and not a medical review
Medical review status
What was approved: regulator fact
On 11 June 2025, China's NMPA approved zolbetuximab for injection, trade name VYLOY, for marketing in China.
The official indication states use with fluorouracil- and platinum-based chemotherapy as first-line treatment for unresectable or metastatic CLDN18.2-positive, HER2-negative gastric or GEJ adenocarcinoma.
Zolbetuximab is a monoclonal antibody targeting CLDN18.2. TanyaKanker cites the regulator wording without changing its meaning.
What is still uncertain: availability, cost, and Indonesia status
Approval, availability, and payment coverage are separate. NMPA approval applies to China; Indonesian approval and access must be confirmed through the doctor or care facility.
- Availability: whether a destination hospital actually provides it for international patients must be confirmed directly.
- Criteria: CLDN18.2-positive, HER2-negative, advanced, first-line status is assessed by the doctor using clear marker results.
- Cost: TanyaKanker does not publish a price. Ask the destination facility for a written component estimate.
Penjelasan visual
The CLDN18.2 journey in stomach cancer
From tissue testing to the questions worth asking after the result is available.
This diagram explains the sequence of assessment and discussion. It is not treatment advice or an eligibility decision.
Stomach cancer cells are examined
Assessment is performed on tumour tissue, not blood.
CLDN18.2 testing
The result is usually reported with a staining percentage and intensity.
Positive or negative result
Assessment thresholds may differ between facilities.
Options are discussed
Including options approved in a country and those still under investigation.
Clinical trial or second opinion
The next step depends on the records and the patient's condition.
A marker name in a report is the start of a discussion, not a decision.
What this means for discussion with the doctor
For families with a CLDN18.2-positive result, this approval adds a real option to discuss, not a promise of access for the case.
Useful questions include whether CLDN18.2 has been tested with a clear score and threshold, whether HER2 has been assessed, and which options fit the combined results.
Limits of this explainer
The verified fact is the Chinese regulator decision and its stated indication. This article does not assess individual suitability, promise an outcome, or recommend treatment.
Langkah berikutnya
If this question relates to your condition, build a structured case summary so your questions and documents are ready to discuss with a doctor.
